메뉴 건너뛰기




Volumn 106, Issue 2, 2011, Pages 191-202

High platelet reactivity and clinical outcome - fact and fiction

Author keywords

Antiplatelet agents; P2Y12 receptor; Platelet function testing; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; PACLITAXEL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RAPAMYCIN; TICAGRELOR;

EID: 79961072519     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-01-0040     Document Type: Article
Times cited : (66)

References (99)
  • 1
    • 33645052218 scopus 로고    scopus 로고
    • ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)
    • Smith SC, Jr. Feldman TE, Hirshfeld JW, Jr. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
    • (2006) Circulation , vol.113
    • Smith Jr., S.C.1    Feldman, T.E.2    Hirshfeld Jr, J.W.3
  • 2
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 3
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 4
    • 0034762075 scopus 로고    scopus 로고
    • Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement
    • Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
    • (2001) Heart , vol.85 , pp. 92-93
    • Muller, I.1    Seyfarth, M.2    Rudiger, S.3
  • 5
    • 0038649988 scopus 로고    scopus 로고
    • Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
    • Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    • (2003) Circulation , vol.107 , pp. 2908-2913
    • Gurbel, P.A.1    Bliden, K.P.2    Hiatt, B.L.3
  • 6
    • 11844256436 scopus 로고    scopus 로고
    • Variability in platelet responsiveness to clopidogrel among 544 individuals
    • Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 246-251
    • Serebruany, V.L.1    Steinhubl, S.R.2    Berger, P.B.3
  • 7
    • 77953911457 scopus 로고    scopus 로고
    • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    • Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 919-933
    • Bonello, L.1    Tantry, U.S.2    Marcucci, R.3
  • 8
    • 60949083948 scopus 로고    scopus 로고
    • Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    • Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 849-856
    • Sibbing, D.1    Braun, S.2    Morath, T.3
  • 9
    • 77955603691 scopus 로고    scopus 로고
    • Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window
    • Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 317-318
    • Sibbing, D.1    Steinhubl, S.R.2    Schulz, S.3
  • 10
    • 38949179203 scopus 로고    scopus 로고
    • Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point
    • Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 690-697
    • Ndrepepa, G.1    Berger, P.B.2    Mehilli, J.3
  • 11
    • 70249101426 scopus 로고    scopus 로고
    • Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH
    • Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
    • (2009) J Thromb Haemost , vol.7 , pp. 1029
    • Cattaneo, M.1    Hayward, C.P.2    Moffat, K.A.3
  • 13
    • 33947328091 scopus 로고    scopus 로고
    • Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance
    • Siller-Matula J, Schrör K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
    • (2007) Thromb Haemost , vol.97 , pp. 385-393
    • Siller-Matula, J.1    Schrör, K.2    Wojta, J.3
  • 14
    • 70549107994 scopus 로고    scopus 로고
    • Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance
    • Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". Am Heart J 2009; 158: 925-932.
    • (2009) Am Heart J , vol.158 , pp. 925-932
    • Serebruany, V.1    Cherala, G.2    Williams, C.3
  • 15
    • 34447274446 scopus 로고    scopus 로고
    • Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention
    • Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
    • (2007) Am J Cardiol , vol.100 , pp. 203-205
    • Sibbing, D.1    von Beckerath, O.2    Schomig, A.3
  • 16
    • 11144355993 scopus 로고    scopus 로고
    • Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted?
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169-174.
    • (2004) J Invasive Cardiol , vol.16 , pp. 169-174
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3
  • 17
    • 23644433510 scopus 로고    scopus 로고
    • Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
    • (2005) Diabetes , vol.54 , pp. 2430-2435
    • Angiolillo, D.J.1    Fernandez-Ortiz, A.2    Bernardo, E.3
  • 18
    • 37549006004 scopus 로고    scopus 로고
    • The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
    • Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
    • (2008) J Thromb Haemost , vol.6 , pp. 54-61
    • Geisler, T.1    Grass, D.2    Bigalke, B.3
  • 19
    • 44349185490 scopus 로고    scopus 로고
    • Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease
    • Geisler T, Kapp M, Gohring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94: 743-747.
    • (2008) Heart , vol.94 , pp. 743-747
    • Geisler, T.1    Kapp, M.2    Gohring-Frischholz, K.3
  • 20
    • 65449170730 scopus 로고    scopus 로고
    • Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention
    • Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103: 1339-1343.
    • (2009) Am J Cardiol , vol.103 , pp. 1339-1343
    • Price, M.J.1    Nayak, K.R.2    Barker, C.M.3
  • 21
    • 76049120468 scopus 로고    scopus 로고
    • A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction
    • Osmancik P, Jirmar R, Hulikova K, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75: 158-166.
    • (2010) Catheter Cardiovasc Interv , vol.75 , pp. 158-166
    • Osmancik, P.1    Jirmar, R.2    Hulikova, K.3
  • 22
    • 78649732206 scopus 로고    scopus 로고
    • Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment
    • Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010; 104: 1193-1200.
    • (2010) Thromb Haemost , vol.104 , pp. 1193-1200
    • Bernlochner, I.1    Steinhubl, S.2    Braun, S.3
  • 23
    • 48449101872 scopus 로고    scopus 로고
    • The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    • Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52: 531-533.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 531-533
    • Bliden, K.P.1    Dichiara, J.2    Lawal, L.3
  • 24
    • 77958505560 scopus 로고    scopus 로고
    • Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • author reply
    • Gurbel PA, Tantry US, Shuldiner AR. Letter by Gurbel et al. regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement". Circulation 2010; 122: e478; author reply e479.
    • (2010) Circulation , vol.122
    • Gurbel, P.A.1    Tantry, U.S.2    Shuldiner, A.R.3
  • 25
    • 67849119987 scopus 로고    scopus 로고
    • Platelet reactivity and stent thrombosis: Still some issues to solve
    • author reply
    • Perez de Prado A, Cuellas C, Diego A, et al. Platelet reactivity and stent thrombosis: still some issues to solve. J Am Coll Cardiol 2009; 54: 666-667; author reply 667-668.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 666-667
    • de Perez, P.A.1    Cuellas, C.2    Diego, A.3
  • 26
    • 57149104093 scopus 로고    scopus 로고
    • Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    • Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148 e1-5.
    • (2009) Am Heart J , vol.157 , Issue.148
    • Siller-Matula, J.M.1    Spiel, A.O.2    Lang, I.M.3
  • 27
    • 64849087438 scopus 로고    scopus 로고
    • Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
    • Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
    • (2009) Thromb Haemost , vol.101 , pp. 714-719
    • Sibbing, D.1    Morath, T.2    Stegherr, J.3
  • 28
    • 38349065084 scopus 로고    scopus 로고
    • Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
    • Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 256-260
    • Gilard, M.1    Arnaud, B.2    Cornily, J.C.3
  • 29
    • 61549124132 scopus 로고    scopus 로고
    • Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
    • Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc 2009; 301: 937-944.
    • (2009) J Am Med Assoc , vol.301 , pp. 937-944
    • Ho, P.M.1    Maddox, T.M.2    Wang, L.3
  • 30
    • 62649164844 scopus 로고    scopus 로고
    • A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
    • Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
    • (2009) CMAJ , vol.180 , pp. 713-718
    • Juurlink, D.N.1    Gomes, T.2    Ko, D.T.3
  • 31
    • 70249144272 scopus 로고    scopus 로고
    • Risk of combining PPIs with thienopyridines: Fact or fiction?
    • Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009; 374: 952-954.
    • (2009) Lancet , vol.374 , pp. 952-954
    • Sibbing, D.1    Kastrati, A.2
  • 32
    • 78149487926 scopus 로고    scopus 로고
    • Clopidogrel with or without omeprazole in coronary artery disease
    • Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
    • (2010) N Engl J Med , vol.363 , pp. 1909-1917
    • Bhatt, D.L.1    Cryer, B.L.2    Contant, C.F.3
  • 33
    • 70249139788 scopus 로고    scopus 로고
    • Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
    • O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997.
    • (2009) Lancet , vol.374 , pp. 989-997
    • O'Donoghue, M.L.1    Braunwald, E.2    Antman, E.M.3
  • 34
    • 64849105131 scopus 로고    scopus 로고
    • Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit?
    • Serebruany V, Goto S. Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit? Thromb Haemost 2009; 101: 607-609.
    • (2009) Thromb Haemost , vol.101 , pp. 607-609
    • Serebruany, V.1    Goto, S.2
  • 35
    • 65349111293 scopus 로고    scopus 로고
    • The drug-drug interaction between proton pump inhibitors and clopidogrel
    • Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 699-700.
    • (2009) CMAJ , vol.180 , pp. 699-700
    • Lau, W.C.1    Gurbel, P.A.2
  • 36
    • 0037422534 scopus 로고    scopus 로고
    • Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction
    • Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
    • (2003) Circulation , vol.107 , pp. 32-37
    • Lau, W.C.1    Waskell, L.A.2    Watkins, P.B.3
  • 37
    • 77952048536 scopus 로고    scopus 로고
    • The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
    • Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
    • (2010) Thromb Haemost , vol.103 , pp. 920-925
    • Harmsze, A.M.1    Robijns, K.2    van Werkum, J.W.3
  • 38
    • 54349121974 scopus 로고    scopus 로고
    • Calcium-channel blockers reduce the antiplatelet effect of clopidogrel
    • Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 1557-1563
    • Siller-Matula, J.M.1    Lang, I.2    Christ, G.3
  • 39
    • 77952400164 scopus 로고    scopus 로고
    • Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel
    • Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010; 31: 1205-1211.
    • (2010) Eur Heart J , vol.31 , pp. 1205-1211
    • Sibbing, D.1    von Beckerath, N.2    Morath, T.3
  • 40
    • 79952444959 scopus 로고    scopus 로고
    • Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting
    • Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161: 605-610.
    • (2011) Am Heart J , vol.161 , pp. 605-610
    • Sarafoff, N.1    Neumann, L.2    Morath, T.3
  • 41
    • 0042780283 scopus 로고    scopus 로고
    • Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    • Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-924.
    • (2003) Circulation , vol.108 , pp. 921-924
    • Saw, J.1    Steinhubl, S.R.2    Berger, P.B.3
  • 42
    • 7544244139 scopus 로고    scopus 로고
    • Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting
    • Nov
    • Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004 Nov;25(21):1898-902.
    • (2004) Eur Heart J , vol.25 , Issue.21 , pp. 1898-902
    • Gorchakova, O.1    von Beckerath, N.2    Gawaz, M.3
  • 43
    • 53649098316 scopus 로고    scopus 로고
    • Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation
    • Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008; 264: 472-480.
    • (2008) J Intern Med , vol.264 , pp. 472-480
    • Sarafoff, N.1    Ndrepepa, G.2    Mehilli, J.3
  • 44
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    • (2009) N Engl J Med , vol.360 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 45
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
    • (2009) J Am Med Assoc , vol.302 , pp. 849-857
    • Shuldiner, A.R.1    O'Connell, J.R.2    Bliden, K.P.3
  • 46
    • 77955416969 scopus 로고    scopus 로고
    • Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
    • Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-1693.
    • (2010) J Thromb Haemost , vol.8 , pp. 1685-1693
    • Sibbing, D.1    Gebhard, D.2    Koch, W.3
  • 47
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3
  • 48
    • 65249145201 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
    • Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
    • (2009) Eur Heart J , vol.30 , pp. 916-922
    • Sibbing, D.1    Stegherr, J.2    Latz, W.3
  • 49
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
    • (2009) N Engl J Med , vol.360 , pp. 363-375
    • Simon, T.1    Verstuyft, C.2    Mary-Krause, M.3
  • 50
    • 73149119363 scopus 로고    scopus 로고
    • Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    • Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
    • (2010) Drug Metab Dispos , vol.38 , pp. 92-99
    • Kazui, M.1    Nishiya, Y.2    Ishizuka, T.3
  • 51
    • 1642453779 scopus 로고    scopus 로고
    • Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    • Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-171.
    • (2004) Circulation , vol.109 , pp. 166-171
    • Lau, W.C.1    Gurbel, P.A.2    Watkins, P.B.3
  • 52
    • 43049179414 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    • Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1925-1934
    • Trenk, D.1    Hochholzer, W.2    Fromm, M.F.3
  • 53
    • 78049326068 scopus 로고    scopus 로고
    • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis
    • Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J Am Med Assoc 2010; 304: 1821-1830.
    • (2010) J Am Med Assoc , vol.304 , pp. 1821-1830
    • Mega, J.L.1    Simon, T.2    Collet, J.P.3
  • 54
    • 77953896604 scopus 로고    scopus 로고
    • Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis
    • Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 134-143
    • Hulot, J.S.1    Collet, J.P.2    Silvain, J.3
  • 55
    • 77955425743 scopus 로고    scopus 로고
    • ACCF/AHA Clopidogrel clinical alert: Approaches to the FDA "boxed warning": A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
    • Holmes DR, Jr., Dehmer GJ, Kaul S, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122: 537-557.
    • (2010) Circulation , vol.122 , pp. 537-557
    • Holmes Jr., D.R.1    Dehmer, G.J.2    Kaul, S.3
  • 56
    • 77955416969 scopus 로고    scopus 로고
    • Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
    • Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-1693.
    • (2010) J Thromb Haemost , vol.8 , pp. 1685-1693
    • Sibbing, D.1    Gebhard, D.2    Koch, W.3
  • 57
    • 78049433100 scopus 로고    scopus 로고
    • Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    • Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
    • (2010) N Engl J Med , vol.363 , pp. 1704-1714
    • Pare, G.1    Mehta, S.R.2    Yusuf, S.3
  • 58
    • 30344457586 scopus 로고    scopus 로고
    • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    • Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 103-113
    • Sim, S.C.1    Risinger, C.2    Dahl, M.L.3
  • 59
    • 77958100874 scopus 로고    scopus 로고
    • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial
    • Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
    • (2010) Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1    James, S.2    Storey, R.F.3
  • 61
    • 77958105401 scopus 로고    scopus 로고
    • Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis
    • Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
    • (2010) Lancet , vol.376 , pp. 1312-1319
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 62
    • 78651239845 scopus 로고    scopus 로고
    • Paraoxonase-1 is a major determinant of clopidogrel efficacy
    • Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
    • (2011) Nat Med , vol.17 , pp. 110-116
    • Bouman, H.J.1    Schomig, E.2    van Werkum, J.W.3
  • 63
    • 0030590746 scopus 로고    scopus 로고
    • Blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    • CAPRIE Steering Committee
    • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
    • (1996) Lancet , vol.348 , pp. 1329-1339
    • Randomised, A.1
  • 64
    • 0035967496 scopus 로고    scopus 로고
    • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
    • Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-2578.
    • (2001) Circulation , vol.103 , pp. 2572-2578
    • Steinhubl, S.R.1    Talley, J.D.2    Braden, G.A.3
  • 65
    • 0038354521 scopus 로고    scopus 로고
    • Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
    • Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
    • (2003) Catheter Cardiovasc Interv , vol.59 , pp. 295-302
    • Barragan, P.1    Bouvier, J.L.2    Roquebert, P.O.3
  • 66
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1    Shenkman, B.2    Guetta, V.3
  • 67
    • 27644536235 scopus 로고    scopus 로고
    • Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study
    • Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1820-1826
    • Gurbel, P.A.1    Bliden, K.P.2    Guyer, K.3
  • 68
    • 33750479499 scopus 로고    scopus 로고
    • Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    • Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 1742-1750
    • Hochholzer, W.1    Trenk, D.2    Bestehorn, H.P.3
  • 69
    • 34250020766 scopus 로고    scopus 로고
    • Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
    • Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 2312-2317
    • Buonamici, P.1    Marcucci, R.2    Migliorini, A.3
  • 70
    • 44949173754 scopus 로고    scopus 로고
    • Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    • Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
    • (2008) Eur Heart J , vol.29 , pp. 992-1000
    • Price, M.J.1    Endemann, S.2    Gollapudi, R.R.3
  • 71
    • 77249113768 scopus 로고    scopus 로고
    • Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    • Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
    • (2010) J Am Med Assoc , vol.303 , pp. 754-762
    • Breet, N.J.1    van Werkum, J.W.2    Bouman, H.J.3
  • 72
    • 74749094606 scopus 로고    scopus 로고
    • Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
    • Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351-359.
    • (2010) J Thromb Haemost , vol.8 , pp. 351-359
    • Siller-Matula, J.M.1    Christ, G.2    Lang, I.M.3
  • 73
    • 77953159705 scopus 로고    scopus 로고
    • Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function
    • Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210-1217.
    • (2010) Thromb Haemost , vol.103 , pp. 1210-1217
    • Judge, H.M.1    Buckland, R.J.2    Sugidachi, A.3
  • 74
    • 34447636769 scopus 로고    scopus 로고
    • Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
    • Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
    • (2007) J Thromb Haemost , vol.5 , pp. 1630-1636
    • Bonello, L.1    Paganelli, F.2    Arpin-Bornet, M.3
  • 75
    • 56549090507 scopus 로고    scopus 로고
    • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
    • Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
    • (2008) Platelets , vol.19 , pp. 595-604
    • Gurbel, P.A.1    Antonino, M.J.2    Bliden, K.P.3
  • 76
    • 59849120163 scopus 로고    scopus 로고
    • Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
    • Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242.
    • (2009) Circulation , vol.119 , pp. 237-242
    • Marcucci, R.1    Gori, A.M.2    Paniccia, R.3
  • 77
    • 36949000480 scopus 로고    scopus 로고
    • The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
    • Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
    • (2007) Thromb Haemost , vol.98 , pp. 1329-1334
    • Blindt, R.1    Stellbrink, K.2    de Taeye, A.3
  • 78
    • 79956319559 scopus 로고    scopus 로고
    • Standard versus high-dose clopidogrel according to platelet function testing after PCI: Results of the GRAVITAS trial
    • Price MJ. Standard versus high-dose clopidogrel according to platelet function testing after PCI: Results of the GRAVITAS trial. Circulation 2010; 122: 2215-2226.
    • (2010) Circulation , vol.122 , pp. 2215-2226
    • Price, M.J.1
  • 79
    • 34548542073 scopus 로고    scopus 로고
    • Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis
    • Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
    • (2007) Lancet , vol.370 , pp. 937-948
    • Stettler, C.1    Wandel, S.2    Allemann, S.3
  • 80
    • 77953914576 scopus 로고    scopus 로고
    • The Case for Routine Genotyping in Dual-Antiplatelet Therapy
    • Damani SB, Topol EJ. The Case for Routine Genotyping in Dual-Antiplatelet Therapy. J Am Coll Cardiol 2010; 56: 109-111.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 109-111
    • Damani, S.B.1    Topol, E.J.2
  • 81
    • 2142818494 scopus 로고    scopus 로고
    • The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition
    • Gurbel PA, Bliden KP, Hiatt BL. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. J Thromb Haemost 2003; 1: 1319-1321.
    • (2003) J Thromb Haemost , vol.1 , pp. 1319-1321
    • Gurbel, P.A.1    Bliden, K.P.2    Hiatt, B.L.3
  • 82
    • 0037406216 scopus 로고    scopus 로고
    • Durability of platelet inhibition by clopidogrel
    • Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 91: 1123-1125.
    • (2003) Am J Cardiol , vol.91 , pp. 1123-1125
    • Gurbel, P.A.1    Bliden, K.P.2
  • 83
    • 78651082582 scopus 로고    scopus 로고
    • Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients
    • Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112.
    • (2011) Thromb Haemost , vol.105 , pp. 107-112
    • Jaitner, J.1    Stegherr, J.2    Morath, T.3
  • 84
    • 74249104162 scopus 로고    scopus 로고
    • Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
    • Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
    • (2010) Thromb Haemost , vol.103 , pp. 151-159
    • Sibbing, D.1    Morath, T.2    Braun, S.3
  • 85
    • 73949100670 scopus 로고    scopus 로고
    • Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
    • Geisler T, Zurn C, Simonenko R, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
    • (2010) Eur Heart J , vol.31 , pp. 59-66
    • Geisler, T.1    Zurn, C.2    Simonenko, R.3
  • 86
    • 0027531953 scopus 로고
    • A method to determine the optimal intensity of oral anticoagulant therapy
    • Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
    • (1993) Thromb Haemost , vol.69 , pp. 236-239
    • Rosendaal, F.R.1    Cannegieter, S.C.2    van der Meer, F.J.3
  • 87
    • 74749097435 scopus 로고    scopus 로고
    • Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
    • Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
    • (2010) J Thromb Haemost , vol.8 , pp. 250-256
    • Sibbing, D.1    Schulz, S.2    Braun, S.3
  • 88
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
    • Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1404-1411
    • Bonello, L.1    Camoin-Jau, L.2    Arques, S.3
  • 89
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
    • (2009) Am J Cardiol , vol.103 , pp. 5-10
    • Bonello, L.1    Camoin-Jau, L.2    Armero, S.3
  • 90
    • 45549084213 scopus 로고    scopus 로고
    • Pharmacokinetics of clopidogrel in patients with stent thrombosis
    • Sibbing D, Taubert D, Schomig A, et al. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008; 6: 1230-1232.
    • (2008) J Thromb Haemost , vol.6 , pp. 1230-1232
    • Sibbing, D.1    Taubert, D.2    Schomig, A.3
  • 91
    • 70349785594 scopus 로고    scopus 로고
    • Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
    • Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329.
    • (2009) EuroIntervention , vol.5 , pp. 325-329
    • Cuisset, T.1    Cayla, G.2    Frere, C.3
  • 92
    • 33645982865 scopus 로고    scopus 로고
    • High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
    • Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
    • (2006) J Thromb Haemost , vol.4 , pp. 542-549
    • Cuisset, T.1    Frere, C.2    Quilici, J.3
  • 93
    • 77951615507 scopus 로고    scopus 로고
    • Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation
    • Eshtehardi P, Windecker S, Cook S, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010; 159: 891-898 e1.
    • (2010) Am Heart J , vol.159
    • Eshtehardi, P.1    Windecker, S.2    Cook, S.3
  • 94
    • 35048856897 scopus 로고    scopus 로고
    • ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome
    • Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
    • (2007) Thromb Haemost , vol.98 , pp. 838-843
    • Frere, C.1    Cuisset, T.2    Quilici, J.3
  • 95
    • 33749503499 scopus 로고    scopus 로고
    • Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
    • Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
    • (2006) Eur Heart J , vol.27 , pp. 2420-2425
    • Geisler, T.1    Langer, H.2    Wydymus, M.3
  • 96
    • 49349114160 scopus 로고    scopus 로고
    • Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents
    • Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 734-739
    • Gori, A.M.1    Marcucci, R.2    Migliorini, A.3
  • 97
    • 27644465874 scopus 로고    scopus 로고
    • Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study
    • Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1827-1832
    • Gurbel, P.A.1    Bliden, K.P.2    Samara, W.3
  • 98
    • 73449106079 scopus 로고    scopus 로고
    • High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
    • Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120: 2214-2221.
    • (2009) Circulation , vol.120 , pp. 2214-2221
    • Migliorini, A.1    Valenti, R.2    Marcucci, R.3
  • 99
    • 51649108832 scopus 로고    scopus 로고
    • Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study
    • Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52: 1128-1133.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 1128-1133
    • Patti, G.1    Nusca, A.2    Mangiacapra, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.